Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

BRAFV600E is the most represented somatic point mutation in cutaneous melanoma, thus providing a unique molecular marker for this disease. The development of efficient methods for its detection in free circulating DNA of patients may lead to the improvement of diagnostic and prognostic tools. With this aim, we evaluated whether BRAFV600E represents a detectable marker in the plasma/serum from melanoma patients in a pilot study. Circulating cell‐free DNA was extracted from the serum or plasma of 15 healthy donors and 41 melanoma patients at different clinical stages and obtained either presurgery or after surgery during follow‐up. Quantitative analysis showed higher levels of circulating free DNA in patients compared to controls, with the highest levels detected in samples obtained presurgery and at stage IV. Four different PCR methods were compared for their capacity to amplify a few copies of BRAFV600E in wild‐type DNA. BRAFV600E was detectable in circulating DNA of 12 patients and in none of the controls; only 1 PCR method reproducibly amplified BRAFV600E. Positive samples were obtained from 8/13 patients at stage IV and from 4/24 patients at stage III, but not in 4 patients at stage I–II; half of the positives were obtained presurgery and half at follow‐up. Correspondence between circulating DNA and related tumors were examined for 20 patients, and a correlation was found for stage IV patients. In conclusion, this method can be utilized for monitoring the disease in stage IV melanoma patients but it appears unsatisfactory for the early detection of melanoma. © 2007 Wiley‐Liss, Inc.

[1]  S. O’Day,et al.  Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. , 2006, Cancer research.

[2]  D. Morton,et al.  Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Mirmohammadsadegh,et al.  Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[4]  L. Mariani,et al.  Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. , 2005, Journal of the National Cancer Institute.

[5]  S. O’Day,et al.  Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[7]  H. Müller,et al.  Circulating Nucleic Acids in Plasma or Serum (CNAPS) as Prognostic and Predictive Markers in Patients with Solid Neoplasias , 2005, Disease markers.

[8]  D. Hoon,et al.  Molecular markers in malignant cutaneous melanoma: Gift horse or one‐trick pony? , 2005, Journal of cellular biochemistry.

[9]  James S Goydos,et al.  Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management , 2005, Current oncology reports.

[10]  Dirk Strumberg,et al.  Raf Kinase Inhibitors in Oncology , 2005, Oncology Research and Treatment.

[11]  D. Hoon.  Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma? , 2004, Nature Clinical Practice Oncology.

[12]  M. Daniotti,et al.  Genetic progression of metastatic melanoma. , 2004, Cancer letters.

[13]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[14]  D. Elashoff,et al.  Allelic Imbalance on 12q22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome , 2004, Cancer Research.

[15]  S. O’Day,et al.  Quantification of Circulating DNA in the Plasma and Serum of Cancer Patients , 2004, Annals of the New York Academy of Sciences.

[16]  D. Morton,et al.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients , 2004, Oncogene.

[17]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[18]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[19]  E. Thiel,et al.  Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2004, Clinical Cancer Research.

[20]  R. Elashoff,et al.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. , 2004, Journal of the National Cancer Institute.

[21]  L. Kanter,et al.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  T. Yamashita,et al.  Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction. , 2003, Journal of dermatological science.

[23]  D. Speiser,et al.  Lack of BRAF mutations in uveal melanoma. , 2003, Cancer research.

[24]  C. Goessl.  Diagnostic potential of circulating nucleic acids for oncology , 2003, Expert review of molecular diagnostics.

[25]  R. Stahel,et al.  Circulating DNA: a new diagnostic gold mine? , 2002, Cancer treatment reviews.

[26]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[27]  M T Landi,et al.  Combined risk factors for melanoma in a Mediterranean population , 2001, British Journal of Cancer.

[28]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Morton,et al.  Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. , 2001, Cancer research.

[30]  M. Busch,et al.  Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma , 2001, Transfusion.

[31]  L. Naldi,et al.  Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the Italian population , 2000, Cancer.

[32]  G. Sorenson,et al.  Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Turner,et al.  Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. , 1999, Cancer research.

[34]  D. Garrison,et al.  Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Pittman,et al.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction , 1991, The Lancet.

[36]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .

[37]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[38]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[39]  P. Ascierto,et al.  Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.